Centre of Human Drug Research, Zernikedreef 10, 2333 CL, Leiden, The Netherlands.
Br J Clin Pharmacol. 2011 Oct;72(4):538-46. doi: 10.1111/j.1365-2125.2011.03946.x.
Biochemical characterization of the haemostatic system has advanced significantly in the past decades. Sub-systems, such as coagulation, fibrinolysis, blood cells and platelets and the vessel wall have been studied by specialists, mostly separately and independently. The time has come to integrate the approaches, and, in particular, to develop tests to document the state of the whole system and to have available adequate pharmacodynamic tests to evaluate treatments. Many examples are available to show that traditional general methods of clotting and lysis do not provide the information that is desired. The present tendency is to use specific methods for specific factors or effects which are very limited in pharmacological information. There is also increasing awareness of the occurrence of rather broad interindividual variability in the haemostatic system. This suggests that individually tailored treatments are required. This is the more relevant since haemostasis is a balance and treatment should be positioned between efficacy and safety. The conclusion is reached that there is a need for integrated or global methods or sets of methods that reflect the complexity and individual status appropriately and allow the practitioner to judge the effects of interventions and their individual aspects.
在过去的几十年中,止血系统的生化特征得到了显著的发展。亚系统,如凝血、纤溶、血细胞和血小板以及血管壁,已经被专家们进行了研究,主要是分开和独立地进行。现在是时候整合这些方法了,特别是要开发测试来记录整个系统的状态,并提供足够的药效学测试来评估治疗效果。有许多例子可以表明,传统的一般凝血和溶解方法并不能提供所需的信息。目前的趋势是使用针对特定因素或效应的特定方法,但这些方法在药理学信息方面非常有限。人们也越来越意识到止血系统中存在相当广泛的个体间变异性。这表明需要个体化的治疗方法。这一点更加重要,因为止血是一种平衡,治疗应该在疗效和安全性之间定位。因此得出结论,需要综合或整体的方法或方法集,以适当反映复杂性和个体状态,并允许从业者判断干预措施及其个体方面的效果。